Dimensional Fund Advisors LP Has $225.30 Million Stock Holdings in Tenet Healthcare Corporation $THC

Dimensional Fund Advisors LP boosted its holdings in shares of Tenet Healthcare Corporation (NYSE:THC - Free Report) by 12.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,675,199 shares of the company's stock after buying an additional 181,667 shares during the period. Dimensional Fund Advisors LP owned approximately 1.80% of Tenet Healthcare worth $225,297,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of THC. Mariner LLC lifted its position in shares of Tenet Healthcare by 24.6% in the fourth quarter. Mariner LLC now owns 8,604 shares of the company's stock worth $1,086,000 after purchasing an additional 1,697 shares in the last quarter. GeoWealth Management LLC increased its stake in Tenet Healthcare by 39.8% in the 4th quarter. GeoWealth Management LLC now owns 295 shares of the company's stock valued at $37,000 after buying an additional 84 shares during the period. Forum Financial Management LP boosted its stake in shares of Tenet Healthcare by 43.5% during the 4th quarter. Forum Financial Management LP now owns 2,469 shares of the company's stock valued at $312,000 after buying an additional 749 shares during the period. First Trust Advisors LP grew its holdings in shares of Tenet Healthcare by 11.6% during the 4th quarter. First Trust Advisors LP now owns 305,858 shares of the company's stock valued at $38,608,000 after acquiring an additional 31,815 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in shares of Tenet Healthcare by 8.3% in the fourth quarter. MetLife Investment Management LLC now owns 53,607 shares of the company's stock worth $6,767,000 after acquiring an additional 4,093 shares during the last quarter. 95.44% of the stock is owned by hedge funds and other institutional investors.

Tenet Healthcare Stock Performance

THC opened at $172.04 on Monday. The company has a quick ratio of 1.63, a current ratio of 1.71 and a debt-to-equity ratio of 2.39. The stock's 50 day moving average price is $167.18 and its two-hundred day moving average price is $148.49. The firm has a market capitalization of $15.20 billion, a P/E ratio of 11.01, a price-to-earnings-growth ratio of 0.74 and a beta of 1.52. Tenet Healthcare Corporation has a 12-month low of $109.82 and a 12-month high of $185.25.

Tenet Healthcare (NYSE:THC - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.84 by $1.18. Tenet Healthcare had a net margin of 7.17% and a return on equity of 24.69%. The business had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.16 billion. During the same quarter in the previous year, the firm posted $2.31 earnings per share. Tenet Healthcare's revenue was up 3.2% compared to the same quarter last year. On average, equities analysts forecast that Tenet Healthcare Corporation will post 12.24 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Thomas W. Arnst sold 9,786 shares of the company's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $166.00, for a total value of $1,624,476.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director J Robert Kerrey sold 1,222 shares of Tenet Healthcare stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $164.96, for a total transaction of $201,581.12. Following the sale, the director owned 22,377 shares in the company, valued at $3,691,309.92. This represents a 5.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,659 shares of company stock valued at $7,068,604 in the last quarter. 0.81% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

THC has been the topic of a number of recent research reports. The Goldman Sachs Group boosted their target price on Tenet Healthcare from $134.00 to $154.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Truist Financial boosted their price target on Tenet Healthcare from $190.00 to $205.00 and gave the company a "buy" rating in a research note on Wednesday, July 16th. Barclays cut their price objective on shares of Tenet Healthcare from $215.00 to $208.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Bank of America increased their price target on shares of Tenet Healthcare from $165.00 to $180.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Finally, Stephens raised shares of Tenet Healthcare to a "strong-buy" rating in a research note on Monday, June 2nd. Four analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Tenet Healthcare presently has a consensus rating of "Moderate Buy" and a consensus target price of $191.88.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.